文献速递中医儿科中药与中成药合理使用

基于国家药品编码数据库的我国儿童中成药现状调查

Investigation on current situation of Chinese patent medicines for children in China based on the national drug coding database.
PubMed 文献 · Front Pharmacol · 2025-06-12

该研究基于国家药监局国家药品编码数据库,采用描述性统计方法分析儿童中成药的分布、特征及问题。截至2023年5月,共识别1164种儿童中成药,以口服(92.87%)为主,治疗侧重肺系(31.9%)和脾胃系(26.5%)疾病;存在剂量标注不清(56.70%)、疗程缺失(92.01%)及安全性信息不完整等问题,建议开发新药、改善适宜性并完善说明书。

要点

  • 儿童中成药以口服为主(92.87%),治疗集中于肺系和脾胃系疾病。
  • 56.70%的儿童中成药未明确标注年龄剂量,92.01%未规定疗程。
  • 部分品种口感不佳,安全性信息不完整,需完善说明书以保障用药安全。

核心结论

  • 儿童中成药存在可及性有限、适宜性差、研究供应不均衡及安全性标注不足等问题,可能带来用药风险。

研究设计与样本

  • 基于国家药监局国家药品编码数据库,以国药准字Z和国药准字B中成药为研究对象,采用描述性统计方法分析儿童中成药的分布、特征及问题。

主要发现

  • 截至2023年5月,我国有8903个国药准字Z中成药和951个国药准字B中成药,其中识别出1164个儿童中成药。
  • 儿童中成药给药途径以口服为主(92.87%),口味以苦味或甜味为主,部分有不良气味。
  • 治疗领域侧重肺系疾病(31.9%)和脾胃系疾病(26.5%)。
  • 49.66%的药品提及西医病名,63.92%提及中医证型。
  • 56.70%的药品未明确年龄剂量,92.01%未规定疗程,安全性信息不完整,不良反应主要涉及胃肠系统。

临床怎么用

  • 临床选用儿童中成药时,应关注说明书中的年龄剂量和疗程信息,避免超说明书用药。
  • 针对肺系和脾胃系疾病,可优先考虑现有儿童中成药,但需注意口味适宜性和安全性监测。
  • 建议开展上市后评价,完善药品说明书,促进儿童合理用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chinese patent medicine is a crucial component of traditional Chinese medicine, significantly promoting public health. Despite the extensive research on Chinese patent medicine for children, various issues persist in its application. Leveraging the national drug coding standard code database of the National Medical Products Administration (NMPA), this investigation delved into the accessibility of Chinese patent medicines tailored for children, offering a comprehensive overview of the current landscape in China. This analysis serves as a valuable resource for formulating targeted policies to promote the use of Chinese patent medicines for children, guiding drug selection, and facilitating the development of pediatric pharmaceuticals. METHODS: Taking Chinese patent medicines with "National Medicine Approval Number Z" and "National Medicine Approval Number B" from the NMPA National Drug Coding Database as the research subjects, this study systematically analyzed the distribution, characteristics, and existing issues of Chinese patent medicines for children using descriptive statistical methods. RESULTS AND DISCUSSION: As of May 2023, 8,903 approved "National Medicine Approval Number Z" Chinese patent medicines, 951 approved "National Medicine Approval Number B" Chinese patent medicines in China, with 1,164 Chinese patent medicines for children identified. Chinese patent medicines for children are predominantly administered orally (92.87%), while external preparations are limited. The taste profile is primarily bitter or sweet, with some medications having other undesirable flavors. The therapeutic focus is skewed toward pulmonary system diseases (31.9%) and spleen-stomach diseases (26.5%). Notably, 49.66% of the medications mention Western medical disease names, and 63.92% reference traditional Chinese medicine (TCM) syndrome types. Critical gaps include unclear age-specific dosage instructions (56.70%), lack of specified treatment duration (92.01%), and incomplete safety information, with adverse reactions mainly involving the gastrointestinal system. Current issues include the limited availability of Chinese patent medicines for children, poor suitability for children, imbalanced research and supply (over-concentration in pulmonary and spleen-stomach disorders), and inadequate safety labeling in drug instructions, posing potential risks. Recommendations include developing new Chinese patent medicines for children, improving drug suitability, conducting post-marketing evaluations, and refining drug labeling to ensure safe and rational pediatric medication use.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu H, Rong P, Zhang Y, et al. Investigation on current situation of Chinese patent medicines for children in China based on the national drug coding database. Front Pharmacol. 2025. PMID: 40575788. doi:10.3389/fphar.2025.1626274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。